Ji Hyun Chang1, Kyung Hwan Shin2, Seung Do Ahn3, Hae Jin Park4, Eui Kyu Chie5, Jin Ho Kim5, Su Ssan Kim6, Yong Bae Kim7, Won Park8, Yeon-Joo Kim9, Hyun Soo Shin10, Jin Hee Kim11, Sun Young Lee12, Kyubo Kim13, Kyung Ran Park14, Bae Kwon Jeong15, Ja Young Kim16, Suzy Kim1. 1. Department of Radiation Oncology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea. 2. Department of Radiation Oncology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Korea. radiat@snu.ac.kr. 3. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea. sdahn@amc.seoul.kr. 4. Department of Radiation Oncology, Hanyang University Hospital, Seoul, Korea. 5. Department of Radiation Oncology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Korea. 6. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea. 7. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea. 8. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 9. Department of Radiation Oncology, Proton Therapy Center, National Cancer Center, Goyang, Korea. 10. Department of Radiation Oncology, CHA University School of Medicine, Pocheon, Korea. 11. Department of Radiation Oncology, Keimyung University School of Medicine, Daegu, Korea. 12. Department of Radiation Oncology, Chonbuk National University Hospital, Jeonju, Korea. 13. Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Korea. 14. Department of Radiation Oncology, Ewha Womans University Mokdong Hospital, Seoul, Korea. 15. Department of Radiation Oncology, Gyeongsang National University School of Medicine, Jinju, Korea. 16. Department of Radiation Oncology, Asan Medical Center, Seoul, Korea.
Abstract
PURPOSE: In correlation with the nodal status in the era of modern radiotherapy, the chest wall recurrence (CWR) rate was investigated in pT1-2N0-1 breast cancer patients after a mastectomy without post-mastectomy radiotherapy (PMRT). METHODS: The data from the patients participating in two South Korean multi-institutional studies (KROG 14-22; N = 1842 and KROG 14-23; N = 1382) were analyzed. In total, 3224 pT1-2N0-1 breast cancer patients who underwent mastectomy without PMRT were analyzed. RESULTS: The median follow-up time was 72.2 months (range 0.8-125.2 months). The overall CWRs during the follow-up period were 1.68% in N0 patients and 2.82% in N1 patients. There was no statistically significant difference in 5-year and 10-year CWR-free survival (CWRFS) between the N0 and N1 patients. Of the 70 patients with CWR, 33 (1% of all the patients) had isolated CWR, and the 10-year overall survival rate in this group was 96.9%. After the propensity score matching of the N0 and N1 groups, there was still no difference in CWRFS by nodal status. CONCLUSIONS: The incidence of CWR in pT1-2N0-1 breast cancer patients is very low, especially with isolated recurrence. Also, the obtained data showed that the nodal status had no impact on CWRFS.
PURPOSE: In correlation with the nodal status in the era of modern radiotherapy, the chest wall recurrence (CWR) rate was investigated in pT1-2N0-1 breast cancerpatients after a mastectomy without post-mastectomy radiotherapy (PMRT). METHODS: The data from the patients participating in two South Korean multi-institutional studies (KROG 14-22; N = 1842 and KROG 14-23; N = 1382) were analyzed. In total, 3224 pT1-2N0-1 breast cancerpatients who underwent mastectomy without PMRT were analyzed. RESULTS: The median follow-up time was 72.2 months (range 0.8-125.2 months). The overall CWRs during the follow-up period were 1.68% in N0 patients and 2.82% in N1 patients. There was no statistically significant difference in 5-year and 10-year CWR-free survival (CWRFS) between the N0 and N1 patients. Of the 70 patients with CWR, 33 (1% of all the patients) had isolated CWR, and the 10-year overall survival rate in this group was 96.9%. After the propensity score matching of the N0 and N1 groups, there was still no difference in CWRFS by nodal status. CONCLUSIONS: The incidence of CWR in pT1-2N0-1 breast cancerpatients is very low, especially with isolated recurrence. Also, the obtained data showed that the nodal status had no impact on CWRFS.